Ligand Pharmaceuticals, Inc. (LGND)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$303.53-1.39%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Ligand Pharmaceuticals, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.1%

+10% or more+5%0%−5%−10% or less

12.13 → 12.12 EPS · FY ending Dec 31, 2027 · 7 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 7 to 7; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	97.34M
EPS	—	3.01
FY 2026 · Annual
Contract revenue	$10M–$20M	—
Revenue	—	289.47M
Revenue from revenue	$35M–$40M	—
EPS	—	9.347
FY 2027 · Annual
Revenue	—	385.49M
EPS	—	12.118

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Adjusted EPS of $8.50-$9.50 in 2026	A primary condition in Ligand Pharmaceuticals, Inc.'s published investment case. The stated target is $8.50-$9.50 per share.	Intact	Adjusted EPS falls below $8.50 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Ligand reaffirmed and raised its 2026 revenue guidance from $245-$285 million to $270-$310 million and adjusted EPS guidance from $8.50-$9.50 to $9.00-$9.50, reflecting acquisition synergies and portfolio strength. This matches the reported revenue growth and acquisition completion, indicating delivery on guidance commitments. Delivery assessment Oct 24, 2026
Close acquisition of XOMA Royalty adding 120+ assets	The acquisition of XOMA Royalty will add over 120 assets and diversify growth.	Intact	Acquisition fails to close by Q3 2026	Acquisition closed 2026-07-14 vs Q3 2026 target 8-K filings confirm the XOMA Royalty merger closed on July 14, 2026, ahead of the Q3 2026 target. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Ligand completed the XOMA Royalty acquisition in 2026-Q2, adding over 120 assets and more than doubling its portfolio to over 200 assets. Revenue grew from $47.6 million in 2025-Q2 to $63.7 million in 2026-Q2, driven by royalty growth. The acquisition is expected to add $0.50 and $1.50 per share to 2026 and 2027 adjusted EPS, respectively. The trajectory is delivering as management has closed the acquisition and reported strong revenue growth. Delivery assessment Oct 24, 2026
Operating income of at least $17 million in Q1 2026	Profit improved with operating income rising to $17.4 million in Q1 2026.	Intact	Operating income falls below $17 million in Q1 FY2026	Operating income: $8.591M FY2026-Q2; GAAP. Published target: >= $17 million. Target period is not explicitly aligned with this observation. Source published Aug 7, 20268,591,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 00885363-fadd-4474-a2b1-9e18f16a8e2f. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Annual revenue of $270-$310 million in 2026	A primary condition in Ligand Pharmaceuticals, Inc.'s published investment case. The stated target is $270-$310 million.	Intact	Annual revenue falls below $270 million in FY26	Revenue: $63.693M FY2026-Q2; GAAP. Published target: $270-$310 million. Target period is not explicitly aligned with this observation. Source published Aug 7, 202663,693,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 00885363-fadd-4474-a2b1-9e18f16a8e2f. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Ligand reaffirmed and raised its 2026 revenue guidance from $245-$285 million to $270-$310 million and adjusted EPS guidance from $8.50-$9.50 to $9.00-$9.50, reflecting acquisition synergies and portfolio strength. This matches the reported revenue growth and acquisition completion, indicating delivery on guidance commitments. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$12.12

$11.83 → $12.12 · observed estimates

FY2027 revenue$0.39B

$0.38B → $0.39B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$11.83	$375,369,660	7 / 8
2026-07-25	$11.60	$375,369,661	5 / 6
2026-07-26	$11.83	$375,369,660	7 / 8
2026-07-27	$11.83	$375,369,660	7 / 8
2026-07-28	$11.83	$375,369,660	7 / 8
2026-07-29	$11.83	$375,369,660	7 / 8
2026-07-30	$11.83	$375,369,660	7 / 8
2026-07-31	$11.83	$375,369,660	7 / 8
2026-08-01	$11.60	$375,369,661	5 / 6
2026-08-02	$11.83	$375,369,660	7 / 8
2026-08-03	$11.83	$375,369,660	7 / 8
2026-08-04	$11.83	$375,369,660	7 / 8
2026-08-05	$12.05	$377,307,160	7 / 8
2026-08-06	$12.05	$377,307,160	7 / 8
2026-08-07	$12.02	$377,307,161	6 / 7
2026-08-08	$12.02	$377,307,161	6 / 7
2026-08-09	$11.97	$378,437,790	8 / 9
2026-08-10	$11.97	$378,437,790	8 / 9
2026-08-12	$11.95	$378,382,230	8 / 9
2026-08-13	$12.02	$377,307,161	6 / 7
2026-08-14	$12.02	$377,307,161	6 / 7
2026-08-15	$12.02	$377,307,161	6 / 7
2026-08-16	$12.02	$377,307,161	6 / 7
2026-08-17	$12.02	$377,307,161	6 / 7
2026-08-18	$12.02	$377,307,161	7 / 8
2026-08-19	$12.02	$377,307,161	7 / 8
2026-08-20	$12.11	$384,042,298	7 / 8
2026-08-21	$12.11	$384,042,298	7 / 8
2026-08-22	$12.11	$384,042,298	7 / 8
2026-08-23	$12.11	$384,042,298	7 / 8
2026-08-24	$12.11	$384,042,298	7 / 8
2026-08-25	$12.11	$384,042,298	7 / 8
2026-08-26	$12.11	$384,042,298	7 / 8
2026-08-27	$12.11	$384,042,298	7 / 8
2026-08-28	$12.11	$384,042,298	7 / 8
2026-08-29	$12.11	$384,042,298	7 / 8
2026-08-30	$12.11	$384,042,298	7 / 8
2026-08-31	$12.11	$384,042,298	7 / 8
2026-09-01	$12.11	$384,042,298	7 / 8
2026-09-02	$12.11	$384,042,298	7 / 8
2026-09-03	$12.11	$384,042,298	7 / 8
2026-09-04	$12.11	$384,042,298	7 / 8
2026-09-05	$12.11	$384,042,298	7 / 8
2026-09-06	$12.11	$384,042,298	7 / 8
2026-09-07	$12.11	$384,042,298	7 / 8
2026-09-08	$12.11	$384,042,298	7 / 8
2026-09-09	$12.11	$384,042,298	7 / 8
2026-09-10	$12.11	$384,042,298	7 / 8
2026-09-11	$12.11	$384,042,298	7 / 8
2026-09-12	$12.11	$384,042,298	7 / 8
2026-09-13	$12.11	$384,042,298	7 / 8
2026-09-14	$12.11	$384,042,298	7 / 8
2026-09-15	$12.11	$384,042,298	7 / 8
2026-09-16	$12.11	$384,042,298	7 / 8
2026-09-17	$12.11	$384,042,298	7 / 8
2026-09-18	$12.11	$384,042,298	7 / 8
2026-09-19	$12.11	$384,042,298	7 / 8
2026-09-20	$12.11	$384,042,298	7 / 8
2026-09-21	$12.11	$384,042,298	7 / 8
2026-09-22	$12.11	$384,042,298	7 / 8
2026-09-23	$12.13	$384,454,798	7 / 8
2026-09-24	$12.13	$384,454,798	7 / 8
2026-09-25	$12.11	$385,279,798	7 / 8
2026-09-26	$12.11	$385,279,798	7 / 8
2026-09-27	$12.11	$385,279,798	7 / 8
2026-09-28	$12.11	$385,279,798	7 / 8
2026-09-29	$12.11	$385,279,798	7 / 8
2026-09-30	$12.11	$385,279,798	7 / 8
2026-10-01	$12.11	$385,279,798	7 / 8
2026-10-02	$12.11	$385,279,798	7 / 8
2026-10-03	$12.11	$385,279,798	7 / 8
2026-10-04	$12.11	$385,279,798	7 / 8
2026-10-05	$12.11	$385,279,798	7 / 8
2026-10-06	$12.11	$385,279,798	7 / 8
2026-10-07	$12.11	$385,279,798	7 / 8
2026-10-08	$12.11	$385,279,798	7 / 8
2026-10-09	$12.11	$385,279,798	7 / 8
2026-10-10	$12.11	$385,279,798	7 / 8
2026-10-11	$12.11	$385,279,798	7 / 8
2026-10-12	$12.11	$385,279,798	7 / 8
2026-10-13	$12.11	$385,279,798	7 / 8
2026-10-14	$12.11	$385,279,798	7 / 8
2026-10-15	$12.11	$385,279,798	7 / 8
2026-10-16	$12.11	$385,279,798	7 / 8
2026-10-17	$12.11	$385,279,798	7 / 8
2026-10-18	$12.11	$385,279,798	7 / 8
2026-10-19	$12.11	$385,279,798	7 / 8
2026-10-20	$12.12	$385,489,335	7 / 8
2026-10-21	$12.12	$385,489,335	7 / 8
2026-10-22	$12.12	$385,489,335	7 / 8
2026-10-23	$12.12	$385,489,335	7 / 8
2026-10-24	$12.12	$385,489,335	7 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	9	0	0
2026-06-01	9	0	0
2026-07-01	9	0	0
2026-08-01	10	0	0
2026-09-01	11	0	0
2026-10-01	11	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BarclaysSep 25

$345.00New observation · no comparable prior

$0$189.75$379.50

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Adjusted EPS of $8.50-$9.50 in 2026Direct metric needs a verified mapping
Operating income of at least $17 million in Q1 2026Operating income: $8.591M
Annual revenue of $270-$310 million in 2026Revenue: $63.693M

Next proof point

Oct 29, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.4%Typical daily move · historical

Downside history

-14.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Ligand Pharmaceuticals, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth-focused royalty business whose recent expansion is driven by acquisitions and portfolio growth. The long-term thesis is intact, with recent financial performance strong, but management execution has been volatile and confidence in the assessment is medium.

What's priced into Ligand Pharmaceuticals, Inc.

LGND trades at a 1.6-times premium to peers, and the valuation signal is neutral with low model confidence. The evidence flags an elevated risk that the premium rests on expensive valuation and weak execution quality, while the expectations gap is modest.

What the fundamentals likely do

Near term, the completed XOMA Royalty acquisition has expanded the portfolio to more than 200 assets, and second-quarter revenue rose to $63.7 million from $47.6 million a year earlier. Management raised 2026 revenue and adjusted EPS guidance, and the acquisition is expected to add to adjusted EPS in 2026 and 2027; however, recent earnings have been erratic, and a guidance cut would be a meaningful setback.

What Ligand Pharmaceuticals, Inc. hinges on

The multi-year case depends on whether the enlarged royalty portfolio produces sustained growth and management delivers on its raised guidance. Near term, weaker employment data could raise recession concerns for cyclical names, while continued strength from healthcare bellwethers could support the sector backdrop.